- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Fraunhofer and QSC sign deal to enhance broadband SDSL
Fraunhofer and QSC sign deal to enhance broadband SDSLThe Fraunhofer Center for Research in Computer Graphics has entered into a technology partnership agreement with QS Communications, a German provider of Internet access using SDSL (symmetric
Fraunhofer and QSC sign deal to enhance broadband SDSL
The Fraunhofer Center for Research in Computer Graphics has entered into a technology partnership agreement with QS Communications, a German provider of Internet access using SDSL (symmetric DSL) technology. Under terms of the agreement, QSC will gain access to all of the computer and related Internet technologies being developed at Fraunhofers lab in Providence, RI, and Fraunhofer will collaborate with QSC on new technology development related to the use of SDSL in business and residential applications. QSC claims to have the most extensive DSL-based broadband access network in Germany, with more than 420 locations in 24 cities.
- Search Again
- Return To HNN Homepage
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
